Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2018 /
Phase 1 results of NBTXR3 treatment for locally advanced HNSCC in elderly patients

16th - 18th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.11.18
Views: 1553

Dr Caroline Hoffmann - Institut Curie, Paris, France

Dr Caroline Hoffmann speaks with ecancer at the International Society of Geriatric Oncology 2018 conference in Amsterdam about NBTXR3, a new treatment option for locally advanced HNSCC (head and neck squamous cell carcinoma) in elderly patients.

She discusses the data that has been reported from phase 1 and explains how the compound functions as a radio enhancer, how it is administered and how the dose is determined. She also describes the next steps involved in phase 2.

Dr Hoffman speaks about the benefits of adapting this treatment to the specific type of cancer, it's use with elderly patients and how it is compatible with other treatments without increasing the overall toxicities.

However, she does highlight that there is still progress to be made to reach the same level of efficacy as combined chemoradiation with younger patients.

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation